+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Visual Outcome in Macular Retinoblastoma Treated with Primary Chemotherapy

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          In this prospective clinical study, we treated 8 patients (8 eyes, 11 tumors) of macular retinoblastoma with chemotherapy alone, with the aim of avoiding visual loss because of retinal damage by radiation or adjuvant therapy and to assess their final visual outcome. The mean basal dimension of the tumor was 5.0 ± 2.6 mm and the mean height was 2.9 ± 1.3 mm. The fovea was involved in 4 patients (50%) and foveal detachment was present in 3 patients (37.5%). All the patients required less than 6 cycles for tumor control. Four patients (50%) obtained visual acuities ranging from 20/25 to 20/200. Two patients (25%) could gain visual acuity of 20/20. The mean follow-up of patients was 3.24 ± 0.9 years (range 2–5). No patient developed recurrence or metastatic disease. In conclusion, recent trends for ocular salvage have favored chemoreduction followed by focal therapy for the treatment of retinoblastoma. This study supports the consideration of chemotherapy alone as the primary treatment in eyes with macular retinoblastomas, under close supervision, with satisfactory visual outcome.

          Related collections

          Most cited references 2

          • Record: found
          • Abstract: not found
          • Article: not found

          Retinoblastoma treated with primary chemotherapy alone: the significance of tumour size, location, and age

            • Record: found
            • Abstract: found
            • Article: not found

            Vision screening of preverbal children with Teller acuity cards.

            To evaluate the modified Teller visual acuity test as a mass screening tool for testing visual acuity in infants and preverbal children. Prospective case series. A total of 1126 healthy children undergoing mandatory examination at the Mother and Child Health Center. Visual acuity was tested by the modified Teller visual acuity test. Visual acuity was measured in all children. Clinical evaluation was performed in children who failed the Teller acuity test and in a control group. Visual acuity was below the normal range in 5% of the children. In the study group referred for complete eye examination, there were 9% false-negative and 44% false-positive results. In the age range of 12 to 17 months, false-negative and false-positive results were obtained in 5.6% and 50% of the children, respectively. The Teller acuity card procedure can be used for vision screening in preverbal children. Testing was associated with a high rate of false-positive results.

              Author and article information

              S. Karger AG
              December 2003
              30 October 2003
              : 217
              : 6
              : 417-421
              aDr. Rajendra Prasad Centre for Ophthalmic Sciences and bDepartment of Paediatric Oncology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
              73072 Ophthalmologica 2003;217:417–421
              © 2003 S. Karger AG, Basel

              Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

              Page count
              Figures: 2, Tables: 2, References: 17, Pages: 5
              Original Paper

              Vision sciences, Ophthalmology & Optometry, Pathology

              Visual acuity, Macula, Retinoblastoma, Chemotherapy, Fovea


              Comment on this article